Bcl-2 Family

Bcl-2 is a family of evolutionarily related proteins. These proteins govern mitochondrial outer membrane permeabilization (MOMP) and can be either pro-apoptotic (Bax, Bad, Bak and Bok among others) or anti-apoptotic (including Bcl-2 proper, Bcl-xL, and Bcl-w, among an assortment of others). There are a total of 25 genes in the Bcl-2 family known to date. Human genes encoding proteins that belong to this family include: Bak1, Bax, Bal-2, Bok, Mcl-1.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

(+)-Apogossypol

(Apogossypol; NSC736630) Cat. No.: HY-13408

(+)-Apogossypol is a **pan-BCL-2** antagonist. (+)-Apogossypol binds to **Mcl-1**, **Bcl-2** and **Bcl-xL** with EC_{50}s of 2.6, 2.8 and 3.69 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E)-Ferulic acid

((E)-Coniferic acid) Cat. No.: HY-N0060B

(E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

(E)-Ferulic acid-d3

((E)-Coniferic acid-d3) Cat. No.: HY-N0060BS

(E)-Ferulic acid-d3 ((E)-Coniferic acid-d3) is the deuterium labeled (E)-Ferulic acid. (E)-Ferulic acid is a isomer of Ferulic acid which is an aromatic compound, abundant in plant cell walls.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-(-)-Gossypol

(AT-101; R-(-)-gossypol acetic acid) Cat. No.: HY-15464

(R)-(-)-Gossypol (AT-101) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to **Bcl-2**, **Mcl-1** and **Bcl-xL** proteins with K_is of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

(R)-(-)-Gossypol acetic acid (AT-101 (acetic acid); (-)-Gossypol acetic acid; (R)-Gossypol acetic acid)

Cat. No.: HY-15464A

(R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. AT-101 is determined to bind to **Bcl-2**, **Mcl-1** and **Bcl-xL** proteins with K_is of 260±30 nM, 170±10 nM, and 480±40 nM, respectively.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg

(R)-MIK665

Cat. No.: HY-112218A

(R)-MIK665 is the less active enantiomer of MIK665. MIK665 is a special Mcl-1 inhibitor with an IC_{50} of 1.81 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(S)-Gossypol (acetic acid)

((S)-(+)-Gossypol acetic acid) Cat. No.: HY-15464D

(S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of **Bcl-xL** and **Bcl-2** proteins with high affinity.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

2-Hydroxychalcone

Cat. No.: HY-119931

2-hydroxychalcone, a natural flavonoid, is a potent antioxidant, inhibiting lipid peroxidation. 2-Hydroxychalcone induces apoptosis by Bcl-2 downregulation. 2-Hydroxychalcone inhibits the activation of NF-kB.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

A-1155463

Cat. No.: HY-19725

A-1155463 is a highly potent and selective **BCL-XL** inhibitor with an EC_{50} of 70 nM in Molt-4 cell.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

A-1210477

Cat. No.: HY-12468

A-1210477 is a potent and selective inhibitor of **MCL-1** with a K_i of 0.45 nM. A-1210477 specifically binds MCL-1 and promotes **apoptosis** of cancer cells in an MCL-1-dependent manner.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A-1331852

Cat. No.: HY-19741

A-1331852 is an orally available **BCL-XL** selective inhibitor with a K_i of less than 10 pM.



Purity: 99.65%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

A-385358

Cat. No.: HY-16014

A-385358 is a selective inhibitor of **Bcl-X_L** with K_is of 0.80 and 67 nM for **Bcl-X_L** and **Bcl-2**, respectively.



Purity: 98.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ABBV-167

Cat. No.: HY-142209

ABBV-167 is a phosphate prodrug of the **BCL-2** inhibitor venetoclax.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ABT 737-d8

Cat. No.: HY-50907S

ABT 737-d8 is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent **Bcl-2**, **Bcl-x_L** and **Bcl-w** inhibitor with EC_{50}s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

ABT-737

Cat. No.: HY-50907

ABT-737, a BH3 mimetic, is a potent **Bcl-2**, **Bcl-x_L** and **Bcl-w** inhibitor with EC_{50}s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic **apoptotic** pathway.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Anticancer agent 43

Cat. No.: HY-146548

Anticancer Agent 43 is a potent anticancer agent. Anticancer Agent 43 induces **apoptosis** by caspase 3, PARP1, and Bax dependent mechanisms. Anticancer Agent 43 induces DNA damage.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Antitumor agent-55

Cat. No.: HY-146038

Antitumor agent-55 (compound 5q) is a potent antitumor agent. Antitumor agent-55 effectively inhibits PC3, with an IC_{50} of 0.91 μM. Antitumor agent-55 effectively inhibits the colony formation, suppresses the cell migration in PC3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Apogossypolone

(ApoG2)

Cat. No.: HY-19551

Apogossypolone (ApoG2) is an orally active **Bcl-2 family proteins** inhibitor with K_i values of 35, 25 and 660 nM for Bcl-2, Mcl-1 and Bcl-X_L, respectively. Apogossypolone shows antitumor activities, induces cell **apoptosis** and **autophagy**. Apogossypolone also has antifungal activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD-5991

Cat. No.: HY-101533

AZD-5991 is a potent and selective **Mcl-1** inhibitor with an IC_{50} of 0.7 nM in FRET assay and a K_d of 0.17 nM in surface plasmon resonance (SPR) assay.



Purity: 99.50%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZD-5991 (S-enantiomer)

Cat. No.: HY-101533B

AZD-5991 S-enantiomer is the less active enantiomer of AZD-5991. AZD-5991 S-enantiomer is a **Mcl-1** inhibitor with an IC_{50} of 6.3 μM in FRET assay and a K_d of 0.98 μM in surface plasmon resonance (SPR) assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD-5991 Racemate

Cat. No.: HY-101533A

AZD-5991 Racemate is the racemate of AZD-5991. AZD-5991 Racemate is a **Mcl-1** inhibitor with an IC_{50} of <3 nM in FRET assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD4320

Cat. No.: HY-112416

AZD4320 is a novel BH3-mimicking dual **BCL2/BCLxL** inhibitor with IC_{50}s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BAD (103-127) (human)

Cat. No.: HY-P2468

BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of **Bcl-xL**. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAD (103-127) (human), FAM-labeled

Cat. No.: HY-P2499

BAD (103-127) (human), FAM-labeled is a FAM-labeled human BAD (103-127) (HY-P2468). BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BAI1

Cat. No.: HY-103269

BAI1 is a selective and allosteric inhibitor of **BAX**, an apoptosis regulator. BAI1 directly binds to BAX and allosterically inhibits BAX activation. BAI1 has the potential for the research of diseases mediated by BAX-dependent cell death.

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Bak BH3

Cat. No.: HY-P0300

Bak BH3 is derived from the BH3 domain of Bak, can antagonize the function of **Bcl-xL** in cells.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

BAM7

Cat. No.: HY-15341

BAM7 is a direct and selective activator of proapoptotic **BAX** with an IC_{50} of 3.3 μM.



Purity: 99.18%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Bax activator-1

Cat. No.: HY-122760

Bax activator-1 (compound 106) is a **Bax** activator that induces Bax-dependent tumor cell apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bax inhibitor peptide V5

(BIP-V5; BAX Inhibiting Peptide V5)

Cat. No.: HY-P0081

Bax inhibitor peptide V5 (BIP-V5) is a **Bax**-mediated apoptosis inhibitor, used for cancer treatment.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Bcl-2-IN-2

Cat. No.: HY-131247

Bcl-2-IN-2 is a potent and selective **Bcl-2** inhibitor with an IC_{50} of 0.034 nM and also inhibits Bcl-xL with an IC_{50} of 43 nM, showing >1000-fold selectivity for Bcl-2 over Bcl-xL.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bcl-2-IN-4

Cat. No.: HY-143872

Bcl-2-IN-4 is a potent, orally active and selective Bcl-2 inhibitor with an **IC_{50}** of 1.5 nM. Bcl-2-IN-4 displays >200-fold selectivity over Bcl-xL (IC_{50} of 411 nM). Bcl-2-IN-4 inhibits RS4; 11 cell proliferation with an **IC_{50}** of 2.7 nM (WO2021180040A1; compound 2).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bcl-2-IN-5

Cat. No.: HY-143873

Bcl-2-IN-5 is a **BCL-2** inhibitor with **IC_{50}**s of 0.12 nM, 0.14 nM and 0.22 nM for **Bcl-2** wild type, **Bcl-2 D103Y** and **Bcl-2 G101V**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bcl-2-IN-8

Cat. No.: HY-144819

Bcl-2-IN-8 is a potent anticancer agent. Bcl-2-IN-8 shows anti-proliferative activity against both drug-sensitive and drug-resistant cancer cells. Bcl-2-IN-8 induce **apoptosis** and cell cycle arrest at G1 phase. Bcl-2-IN-8 inhibits cell migration in a dose-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bcl-2/Mcl-1-IN-1

Cat. No.: HY-144430

Bcl-2/Mcl-1-IN-1 (compound 3) is a **Bcl-2/Mcl-1** inhibitor, with **K_i**s of 1.19 μM and 4.53 μM for **Mcl-1** and **Bcl-2, respectively. Bcl-2/Mcl-1-IN-1 can be used for the research of cancer.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bcl-2/Mcl-1-IN-2

Cat. No.: HY-144428

Bcl-2/Mcl-1-IN-2 (compound 2) is a **Bcl-2/Mcl-1** inhibitor, with **K_i**s of 0.88 μM and 4.70 μM for **Mcl-1** and **Bcl-2, respectively. Bcl-2/Mcl-1-IN-2 can be used for the research of cancer.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bcl-2/Mcl-1-IN-3

Cat. No.: HY-144431

Bcl-2/Mcl-1-IN-3 (compound 1) is a **Bcl-2/Mcl-1** inhibitor, with **K_i**s of 0.14 μM and 0.23 μM for **Mcl-1** and **Bcl-2, respectively. Bcl-2/Mcl-1-IN-3 can be used for the research of cancer.**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Bcl-xL antagonist 2

Cat. No.: HY-12908

Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of **BCL-X_L** with an **IC_{50}** and **K_i** of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the **apoptosis** of cancer cells.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BCL2-IN-1

Cat. No.: HY-135273

BCL2-IN-1 is a potent **Bcl-2** inhibitor. BCL2-IN-1 binds Bcl-2 with a **K_i** of <0.01 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCL6-IN-4

Cat. No.: HY-136640

BCL6-IN-4 is a potent **B-cell lymphoma 6 (BCL6)** inhibitor with an **IC_{50}** of 97 nM. BCL6-IN-4 has anti-tumor activities.



Purity: 98.44%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BCL6-IN-5

Cat. No.: HY-136774

BCL6-IN-5 is a potent **BCL6** inhibitor exacted from patent WO2018215801A1, example 1n, has a **pIC_{50}** of 5.82.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BCL6-IN-7

Cat. No.: HY-115532

BCL6-IN-7 is a potent BCL6−corepressor interaction inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BCL6-IN-8c

Cat. No.: HY-119402

BCL6-IN-8c is a potent and orally active **B-cell lymphoma 6 (BCL6)-corepressor interaction** inhibitor with an IC_{50} of 0.10 μM in cell-free enzyme-linked immunosorbent assay.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BDA-366

Cat. No.: HY-101083

BDA-366 is a potent **Bcl2** antagonist (K_i = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BH3I-1

(BHI1; BH 3I1)

Cat. No.: HY-100383

BH3I-1 is a **Bcl-2 family** antagonist, which inhibits the binding of the **Bak** BH3 peptide to **Bcl-xL** with a K_i of 2.4±0.2 μM in FP assay. BH3I-1 has a K_d of 5.3 μM against the **p53/MDM2** pair.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BI-3802

Cat. No.: HY-108705

BI-3802 is a highly potent **BCL6** degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC_{50} of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase **SIAH1**. BI-3802 has antitumor activity.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-3812

Cat. No.: HY-111381

BI-3812 is potent and efficacious **BCL6** inhibitor, inhibiting the BTB domain of BCL6, with an IC_{50} of ≤3 nM; BI-3812 has antitumor activity.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Bim-IN-1

Cat. No.: HY-115930

Bim-IN-1 is a potent **Bim** expression inhibitor. Bim-IN-1 reduces **Bim** expression levels and has little inhibitory effect upon protein kinase A activity and minimal toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BM 957

Cat. No.: HY-18106

BM 957 is a potent Bcl-2 and Bcl-xL inhibitor, with K_i**s** of 1.2, <1 nM and IC_{50}**s** of 5.4, 6.0 nM respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BM-1197

Cat. No.: HY-120882

BM-1197 is a potent and selective inhibitor of dual **Bcl-2/Bcl-xL**, with IC_{50}s of 3.5 nM and 5.2 nM for Bcl-2 and Bcl-xL, respectively. BM-1197 exhibits antitumor effects both in vitro and in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BM-1244

Cat. No.: HY-138832

BM-1244 is a potent **Bcl-xL/Bcl-2** inhibitor with K_is of 134 and 450 nM for Bcl- xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC_{50} of 5 nM. (From patent WO2019033119A1).



Purity: 98.77%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg

BT2

Cat. No.: HY-114855

BT2 is a **BCKDC kinase (BDK)** inhibitor with an IC_{50} of 3.19 μM. BT2 binding to **BDK** triggers helix movements in the N-terminal domain, resulting in the dissociation of **BDK** from the branched-chain α-ketoacid dehydrogenase complex (BCKDC).



Purity: 99.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

BTSA1

Cat. No.: HY-123054

BTSA1 is a potent, high affinity and orally active **BAX** activator with an IC_{50} of 250 nM and an EC_{50} of 144 nM. BTSA1 binds with high affinity and specificity to the N-terminal activation site and induces conformational changes to **BAX** leading to **BAX**-mediated **apoptosis**.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Bufarenogin

Cat. No.: HY-N6573

Bufarenogin induces intrinsic **apoptosis** via **Bax** and **ANT** cooperation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Bz 423

(BZ48)

Cat. No.: HY-13108

Bz 423 is a pro-apoptotic 1,4-benzodiazepine with therapeutic properties in murine models of lupus demonstrating selectivity for autoreactive lymphocytes, and activates Bax and Bak.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CCT369260

Cat. No.: HY-129188

CCT369260 (compound 1) is an orally avtive **B-cell lymphoma 6 (BCL6)** inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC_{50} of 520 nM.



Purity: 99.16%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Chelerythrine

Cat. No.: HY-N2359

Chelerythrine is a natural alkaloid, acts as a potent and selective Ca^{2+}/phospholipid-dependent **PKC** antagonist, with an IC_{50} of 0.7 μM. Chelerythrine has antitumor, antidiabetic and anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Chelerythrine chloride

Cat. No.: HY-12048

Chelerythrine chloride is a potent, cell-permeable inhibitor of **protein kinase C**, with an IC_{50} of 660 nM. Chelerythrine chloride inhibits the **Bcl-XL-Bak BH3** peptide binding with IC_{50} of 1.5 μM and displaces Bax from Bcl-XL. Chelerythrine chloride induces **apoptosis** and **autophagy**.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CID5721353

Cat. No.: HY-100502

CID5721353 is an inhibitor of **BCL6** with an IC_{50} value of 212 μM, which corresponds to a K_i of 147 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ciwujianoside B

Cat. No.: HY-N0307

Ciwujianoside B is isolated from Eleutherococcus senticosus leaf, is able to penetrate and work in the brain after the oral administration. Ciwujianoside B significantly enhances object recognition memory.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Clitocine

Cat. No.: HY-118341

Clitocine, an adenosine nucleoside analog isolated from mushroom, is a potent and efficacious **readthrough** agent. Clitocine acts as a suppressor of **nonsense mutations** and can induce the production of p53 protein in cells harboring p53 nonsense-mutated alleles.



Purity: 95.88%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dehydrocorydaline

(13-Methylpalmatine) Cat. No.: HY-N0674

Dehydrocorydaline (13-Methylpalmatine) is an alkaloid that regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**. Dehydrocorydaline elevates **p38 MAPK** activation. Anti-inflammatory and anti-cancer activities.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dehydrocorydaline chloride

(13-Methylpalmatine chloride) Cat. No.: HY-N0674A

Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**. Dehydrocorydaline chloride elevates **p38 MAPK** activation.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

Dehydrocorydaline nitrate

(13-Methylpalmatine nitrate) Cat. No.: HY-N4238

Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. Dehydrocorydaline regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**. Dehydrocorydaline nitrate elevates **p38 MAPK** activation.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Desmorpholinyl Navitoclax-NH-Me

(Desmorpholinyl ABT-263-NH-Me) Cat. No.: HY-131232

Desmorpholinyl Navitoclax-NH-Me is a **Bcl-xL** inhibitor. Desmorpholinyl Navitoclax-NH-Me and a CRBN ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC BCL-XL degrader XZ739 (HY-133557).



Purity: 99.43%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Destruxin B

Cat. No.: HY-N6690

Destruxin B, isolated from entomopathogenic fungus Metarhizium anisopliae, is one of the cyclodepsipeptides with insecticidal and anticancer activities.



Purity: 99.35%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dihydrokaempferol

Cat. No.: HY-N2897

Dihydrokaempferol is isolated from Bauhinia championii (Benth). Dihydrokaempferol induces **apoptosis** and inhibits Bcl-2 and Bcl-xL expression. Dihydrokaempferol is a good candidate for new antiarthritic drugs.



Purity: 99.88%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

dMCL1-2

Cat. No.: HY-128360

dMCL1-2 is a potent and selective PROTAC of **myeloid cell leukemia 1 (MCL1)** (**Bcl-2** family member) based on **Cereblon**, which binds to MCL1 with a K_D of 30 nM. dMCL1-2 activats the cellular apoptosis machinery by degradation of MCL1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

F1324

Cat. No.: HY-100866

F1324 is a potent, high affinity peptidic inhibitor of **B cell lymphoma 6 (BCL6)** with an IC_{50} of 1 nM. F1324 exhibits binding $t_{1/2}$ value of 441 s and has strong inhibition activity against BCL6 PPI.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

F1324 acetate

Cat. No.: HY-100866B

F1324 acetate is a potent, high affinity peptidic inhibitor of **B cell lymphoma 6 (BCL6)**, with an IC_{50} of 1 nM. F1324 acetate exhibits binding $t_{1/2}$ value of 441 s and has strong inhibition activity against BCL6 PPI.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

F1324 TFA

Cat. No.: HY-100866A

F1324 TFA is a potent, high affinity peptidic inhibitor of **B cell lymphoma 6 (BCL6)**, with an IC_{50} of 1 nM. F1324 TFA exhibits binding $t_{1/2}$ value of 441 s and has strong inhibition activity against BCL6 PPI.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FX1

Cat. No.: HY-102027

FX1 is a potent and specific **BCL6** inhibitor, with an IC_{50} of around 35 μM.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Gambogic Acid

(Beta-Guttiferin)

Cat. No.: HY-N0087

Gambogic Acid (Beta-Guttiferin) is derived from the gamboges resin of the tree Garcinia hanburyi. Gambogic Acid (Beta-Guttiferin) inhibits **Bcl-X_L**, **Bcl-2**, **Bcl-W**, **Bcl-B**, **Bfl-1** and **Mcl-1** with IC_{50}s of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM.



Purity: 95.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GL0388

Cat. No.: HY-132173

GL0388 is a **Bax** activator that results in Bax insertion into mitochondrial membrane. GL0388 shows antiproliferative activities against various cancer cells, with IC_{50}s of 0.299-1.57 μM. GL0388 activates Bax and induce Bax-mediated **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gossypol

(BL 193)

Cat. No.: HY-13407

Gossypol binds to **Bcl-xL** protein and **Bcl-2** protein with K_is of 0.5-0.6 μM and 0.2-0.3 mM, respectively.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg

Gossypol (acetic acid)

((±)-Gossypol-acetic acid; BL-193 (acetic acid))

Cat. No.: HY-17510

Gossypol acetic acid ((±)-Gossypol-acetic acid) binds to **Bcl-xL** protein and **Bcl-2** protein with K_is of 0.5-0.6 μM and 0.2-0.3 mM, respectively.



Purity: 99.17%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

HA14-1

Cat. No.: HY-12011

HA14-1 is a **Bcl-2/Bcl-X_L** antagonist. HA14-1 binds the designated pocket on Bcl-2 with the IC_{50} of ≈9 μM in competing with the Bcl-2 binding of Flu-BakBH3, and inhibits its function.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

IDO1/TDO-IN-1

Cat. No.: HY-144778

IDO1/TDO-IN-1 (30) is a potent dual **IDO1** (uncompetitive, K_i of 0.23 μM) and **TDO** (competitive, K_i of 0.73 μM) inhibitor. IDO1/TDO-IN-1 (30) significantly promotes cell apoptosis through the potential mitochondria-mediated Bcl-2/Bax pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

IMB-XH1

Cat. No.: HY-12826

IMB-XH1 is an inhibitor of myeloid cell factor 1 (**Mcl-1**). IMB-XH1 is a non-competitive **Delhi metallo-β-lactamase** (**NDM-1**) inhibitor. The IC_{50}s of IMB-XH1 against metallo-β-lactamases NDM-1, IMP-4, ImiS and L1 are 0.4637 μM, 3.980 μM, 0.2287 μM and 1.158 μM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Isolinderalactone

Cat. No.: HY-N3001

Isolinderalactone suppresses human glioblastoma growth and angiogenic activity through the inhibition of **VEGFR2** activation in endothelial cells. Isolinderalactone suppresses the expression of **B-cell lymphoma 2 (Bcl-2)**, **survi**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Jaceosidin

Cat. No.: HY-N0831

Jaceosidin is a flavonoid isolated from Artemisia vestita, induces apoptosis in cancer cells, activates **Bax** and down-regulates Mcl-1 and c-FLIP expression.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Lisaftoclax

(APG-2575; Bcl-2/Bcl-xl inhibitor 1)

Cat. No.: HY-129179

Lisaftoclax (compound 6) is a dual **Bcl-2** and **Bcl-xl** inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC_{50} values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg

M24

Cat. No.: HY-115928

M24 is a **Mcl-1** selective inhibitor. M24 exhibits good binding affinity against Mcl-1 with K_i value of 0.33 μM. M24 exhibits good anti-proliferative activity and induce apoptosis in HepG2 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Maritoclax

(Marinopyrrole A)

Cat. No.: HY-15613

Maritoclax (Marinopyrrole A) is a novel and specific **Mcl-1** inhibitor with an IC_{50} value of 10.1 μM, and shows >8 fold selectivity than BCL-xl (IC_{50} > 80 μM).



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mcl-1 antagonist 1

Cat. No.: HY-130261

Mcl-1 antagonist 1 is a **Mcl-1** protein antagonist extracted from patent WO2019173181, compound 200.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl-1 inhibitor 3

Cat. No.: HY-133015

Mcl-1 inhibitor 3 (compound 1) is a highly potent and orally activate macrocyclic **Mcl-1** inhibitor (K_i= 0.061 nM; IC_{50}=19 nM in an OPM-2 cell viability assay). Mcl-1 inhibitor 3 shows good pharmacokinetic properties and excellent in vivo efficacy without toxicity.</br>.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl-1 inhibitor 6

Cat. No.: HY-132307

Mcl-1 inhibitor 6 is an orally active, selective **myeloid cell leukemia 1 (Mcl-1)** protein inhibitor with a K_d of 0.23 nM and a K_i of 0.02 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl-1 inhibitor 7

Cat. No.: HY-145825

Mcl-1 inhibitor 7 is a potent **Mcl-1** inhibitor, example 35, extracted from patent WO2020097577A.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl-1 inhibitor 8

Cat. No.: HY-145826

Mcl-1 inhibitor 8 is a **MCL-1** inhibitor, example 228, extracted from patent WO2019222112.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MCL-1/BCL-2-IN-1

Cat. No.: HY-129681

MCL-1/BCL-2-IN-2 (Compound Nap-1) is a potent and selective **Mcl-1** and **Bcl-2** dual inhibitor with IC_{50}s of 4.45 and 3.18 μM, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCL-1/BCL-2-IN-2

Cat. No.: HY-129700

MCL-1/BCL-2-IN-2 (Compound 6) is a potent and selective **Mcl-1** and **Bcl-2** dual inhibitor.



Purity: 98.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MCL-1/BCL-2-IN-3

Cat. No.: HY-129701

MCL-1/BCL-2-IN-3 (Compound 2) is a potent and selective **Mcl-1** and **Bcl-2** dual inhibitor with IC_{50}s of 5.95 and 4.78 μM, respectively.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MCL-1/BCL-2-IN-4

Cat. No.: HY-129702

MCL-1/BCL-2-IN-4 (Compound 7) is a potent and selective **Mcl-1** and **Bcl-2** dual inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl1-IN-1

Cat. No.: HY-16669

Mcl1-IN-1 is an inhibitor of myeloid cell factor 1 (**Mcl-1**) (IC_{50}=2.4 μM).



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mcl1-IN-11

Cat. No.: HY-100762

Mcl1-IN-11 (Compound G) is a selective **Mcl-1** inhibitor, less potent at Bcl-2, with K_is of 0.06 and 4.2 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl1-IN-12

Cat. No.: HY-100763

Mcl1-IN-12 (Compound F) is a selective **Mcl-1** inhibitor, less potent at Bcl-2, with K_is of 0.29 and 3.1 μM, respectively. Anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl1-IN-3

Cat. No.: HY-111468

Mcl1-IN-3 is an inhibitor of **Mcl1** extracted from patent WO2015153959A2, compound example 57; has an IC_{50} and K_i of 0.67 and 0.13 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl1-IN-4

Cat. No.: HY-111467

Mcl1-IN-4 is an inhibitor of **Mcl1** with an IC_{50} of 0.2 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mcl1-IN-8

Cat. No.: HY-122627

Mcl1-IN-8 (Comp8) is a **Mcl-1-PUMA** interface inhibitor, with a K_i of 0.3 μM. Mcl1-IN-8 (Comp8) exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells.



Purity: 95.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Mcl1-IN-9

Cat. No.: HY-128607

Mcl1-IN-9 is a potent **myeloid cell leukemia-1 (Mcl-1)** Inhibitor with an IC_{50} of 446 nM in reengineered BCR-ABL+ B-ALL cells and a K_i of 0.03 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MIK665

(S-64315)

Cat. No.: HY-112218

MIK665 (S-64315), derived from S63845, is a myeloid cell leukemia sequence 1 **(MCL1)** inhibitor. MIK665 has an IC_{50} of 1.81 nM for MCL1.



Purity: 99.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

MIM1

(Inhibitor of Mcl-1) Cat. No.: HY-16695

MIM-1 is an inhibitor of myeloid cell factor 1 (**Mcl-1**).



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

ML311

Cat. No.: HY-101778

ML311 is a potent and selective inhibitor of the **Mcl-1/Bim** interaction.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MSN-125

Cat. No.: HY-120079

MSN-125 is a potent **Bax** and **Bak** oligomerization inhibitor. MSN-125 prevents mitochondrial outer membrane permeabilization (MOMP) with an IC_{50} of 4 μM.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

MSN-50

Cat. No.: HY-118948

MSN-50 is a **Bax** and **Bak** oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection.



Purity: 98.40%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Murizatoclax

(AMG 397) Cat. No.: HY-109184

Murizatoclax (AMG 397) is a potent, selective and orally active inhibitor of **myeloid leukemia 1 (MCL-1)** inhibitor, with a K_i of 15 pM. Murizatoclax competitive binds to the BH3-binding groove of MCL1 with pro-apoptotic BCL-2 family members.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Navitoclax

(ABT-263) Cat. No.: HY-10087

Navitoclax (ABT-263) is a potent and orally active **Bcl-2 family protein** inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-x_L, Bcl-2 and Bcl-w, with a K_i of less than 1 nM.



Purity: 99.97%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Navitoclax-d8

Cat. No.: HY-10087S

Navitoclax-d8 is the deuterium labeled Navitoclax. Navitoclax (ABT-263) is a potent and orally active **Bcl-2 family protein** inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-x_L, Bcl-2 and Bcl-w, with a K_i of less than 1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Navitoclax-piperazine

(ABT-263-piperazine) Cat. No.: HY-44432

Navitoclax-piperazine (ABT-263-piperazine) is a **B-cell lymphoma extra large (BCL-XL)** inhibitor. Navitoclax-piperazine and a VHL ligand for the E3 ubiquitin ligase can be used in the synthesis of PROTAC DT2216 (HY-130604).



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

NPB

Cat. No.: HY-119368

NPB is a specific and potent inhibitor of **BAD phosphorylation at Ser99**, with an IC_{50} of 0.41 μM.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Obatoclax

(GX15-070) Cat. No.: HY-10969A

Obatoclax (GX15-070), a BH3 mimetic, is a pan-**BCL-2** family proteins inhibitor with a K_i of 220 nM for BCL-2. Obatoclax induces **autophagy**-dependent cell death and targets cyclin D1 for proteasomal degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Obatoclax Mesylate

(GX15-070 Mesylate) Cat. No.: HY-10969

Obatoclax Mesylate (GX15-070 Mesylate), a BH3 mimetic, is a pan-**BCL-2** family proteins inhibitor with a K_i of 220 nM for BCL-2. Obatoclax Mesylate induces **autophagy**-dependent cell death and targets cyclin D1 for proteasomal degradation.



Purity: 99.74%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Paris saponin VII

(Chonglou Saponin VII) Cat. No.: HY-N3584

Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii Maxim. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with **Akt/MAPK** and the inhibition of **P-gp**.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Pelcitoclax

(APG-1252) Cat. No.: HY-109185

Pelcitoclax (APG-1252) is a potent **Bcl-2/Bcl-xl** inhibitor with antineoplastic and pro-apoptotic effects.



Purity: 95.53%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

PROTAC Bcl-xL degrader-1

Cat. No.: HY-131188

PROTAC Bcl-xL degrader-1 is a **PROTAC** that comprises a **Bcl-xL** (**Bcl-2** family member) ligand binding group, a linker and an **IAP** E3 ligases binding group.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Bcl-xL degrader-2

Cat. No.: HY-139309

PROTAC Bcl-xL degrader-2 is a potent **Bcl-xL** (**Bcl-2** family member) degrader based on **von Hippel-Lindau** ligand, with an IC_{50} of 0.6 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PROTAC Bcl-xL degrader-3

Cat. No.: HY-132997

PROTAC Bcl-xL degrader-3 is a potent **ROTAC Bcl-xL** degrader (WO2020163823A2, compound 44).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC Bcl-xL ligand-1

Cat. No.: HY-139304

PROTAC Bcl-xL ligand-1 is a ligand for Bcl-xL that can be used in the synthesis of PROTACs.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PROTAC Bcl2 degrader-1

Cat. No.: HY-125876

PROTAC Bcl2 degrader-1 (Compound C5) is a **PROTAC** based on **Cereblon** ligand, which potently and selectively induces the degradation of **Bcl-2** (IC_{50}, 4.94 μM; DC_{50}, 3.0 μM) and **Mcl-1** (IC_{50}, 11.81 μM) by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to...



Purity: 98.78%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PROTAC Mcl1 degrader-1

Cat. No.: HY-125877

PROTAC Mcl1 degrader-1 (compound C3), a proteolysis targeting chimera (PROTAC) based on **Cereblon** ligand, is a potently and selectively **Mcl-1** (**Bcl-2** family member) inhibitor with an IC_{50} of 0.78 μM.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PUMA BH3

Cat. No.: HY-P1562

PUMA BH3 is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of **Bak**, with a K_d of 26 nM.

EEQWAREIGAQLRRMADDLNAQYER

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

PUMA BH3 TFA

Cat. No.: HY-P1562A

PUMA BH3 (TFA) is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of **Bak**, with a K_d of 26 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pyridoclax

(MR-29072)

Cat. No.: HY-12527

Pyridoclax is a potential **Mcl-1** inhibitor.



Purity: 99.74%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

S55746

(BCL201)

Cat. No.: HY-117288

S55746 (BCL201) is a potent, orally active and selective **BCL-2** inhibitor, with a K_i of 1.3 nM and a K_d of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity.



Purity: 99.66%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S55746 hydrochloride

(BCL201 hydrochloride)

Cat. No.: HY-117288A

S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective **BCL-2** inhibitor, with a K_i of 1.3 nM and a K_d of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S63845

Cat. No.: HY-100741

S63845 is a potent and selective **myeloid cell leukemia 1 (MCL1)** inhibitor with a K_d of 0.19 nM for **human MCL1**.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S65487

(VOB560)

Cat. No.: HY-138697

S65487 (VOB560), a potent and selective **BCL-2** inhibitor, is a prodrug of S55746. S65487 is also active on BCL-2 mutations, such as G101V and D103Y. S65487 has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 induces **apoptosis** and has anticaner activities.



Purity: 99.10%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S65487 hydrochloride

(VOB560 hydrochloride)

Cat. No.: HY-138697B

S65487 (VOB560) hydrochloride, a potent and selective **Bcl-2** inhibitor, is a prodrug of S55746. S65487 hydrochloride is also active on BCL-2 mutations, such as G101V and D103Y. S65487 hydrochloride has poor affinity with MCL-1, BFL-1 and BCL-XL.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

S65487 sulfate

(VOB560 sulfate)

Cat. No.: HY-138697A

S65487 (VOB560) sulfate, a potent and selective **Bcl-2** inhibitor, is a prodrug of S55746. S65487 sulfate is also active on BCL-2 mutations, such as G101V and D103Y. S65487 sulfate has poor affinity with MCL-1, BFL-1 and BCL-XL. S65487 sulfate induces **apoptosis** and has anticaner activities.



Purity: 98.08%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sabutoclax

(BI-97C1)

Cat. No.: HY-15191

Sabutoclax is a potent and effective **Bcl-2 Family (Bcl-2, Bcl-XL, Mcl-1, Bfl-1)** inhibitor with IC_{50}s of 0.32 μM, 0.31 μM, 0.20 μM, and 0.62 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Tapotoclax

(AMG-176)

Cat. No.: HY-101565

Tapotoclax (AMG-176) is a potent, selective and orally active **MCL-1** inhibitor, with a K_i of 0.13 nM.



Purity: 99.80%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

TC11

Cat. No.: HY-129478

TC11 is a **MCL1** degrader. TC11 is also a **Caspase-9** and **CDK1** activator. TC11 structurally relates to immunomodulatory drugs as phenylphthalimide derivative. TC11 induces apoptotic death caused by degradation of **MCL1** during prolonged mitotic arrest.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TCPOBOP

Cat. No.: HY-103243

TCPOBOP is a **constitutive androstane receptor (CAR)** agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss. TCPOBOP attenuates Fas-induced murine liver injury by altering **Bcl-2** proteins.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Thevetiaflavone

(Apigenin-5-methyl ether)

Cat. No.: HY-N1157

Thevetiaflavone could upregulate the expression of **Bcl2** and downregulate that of **Bax** and **caspase3**.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

TW-37

Cat. No.: HY-12020

TW-37 is a potent **Bcl-2** inhibitor with K_i values of 260, 290 and 1110 nM for **Mcl-1**, **Bcl-2** and **Bcl-xL**, respectively.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

UMI-77

Cat. No.: HY-18628

UMI-77 is a selective **Mcl-1** inhibitor, which shows high binding affinity to **Mcl-1** (IC_{50}=0.31 μM). UMI-77 binds to the BH3 binding groove of **Mcl-1** with K_i of 490 nM, showing selectivity over other members of anti-apoptotic Bcl-2 members.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

UMI-77-d4

Cat. No.: HY-18628S

UMI-77-d4 is the deuterium labeled UMI-77. UMI-77 is a selective **Mcl-1** inhibitor, which shows high binding affinity to **Mcl-1** (IC_{50}=0.31 μM). UMI-77 binds to the BH3 binding groove of **Mcl-1** with K_i of 490 nM, showing selectivity over other members of anti-apoptotic Bcl-2 members.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Venetoclax

(ABT-199; GDC-0199)

Cat. No.: HY-15531

Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable **Bcl-2** inhibitor with a K_i of less than 0.01 nM. Venetoclax induces **autophagy**.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Venetoclax-d8

(ABT-199-d8; GDC-0199-d8)

Cat. No.: HY-15531S

Venetoclax-d8 is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

VU0661013

Cat. No.: HY-112859

VU661013 is a potent and selective **MCL-1** inhibitor.



Purity: 98.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WEHI-539

Cat. No.: HY-15607

WEHI-539 is a selective inhibitor of **Bcl-XL** with an IC_{50} of 1.1 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WEHI-539 hydrochloride

Cat. No.: HY-15607A

WEHI-539 hydrochloride is a selective inhibitor of **Bcl-XL** with an IC_{50} of 1.1 nM.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

XZ739

Cat. No.: HY-133557

XZ739, a **Cereblon**-dependent PROTAC **BCL-XL** (**Bcl-2** family member) degrader with a DC_{50} value of 2.5 nM in MOLT-4 cells after 16 h treatment. XZ739 also induces cell death through caspase-mediated **apoptosis**.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg